The Stargardt diseases (STGD) market was valued at USD 260.28 Million in 2025 and is expected to grow at a CAGR of 7.20%, reaching USD 521.66 Million by 2035. The market across the 8 major regions is fueled by growing awareness, improved genetic diagnostics, and increasing research funding. Advancements in gene therapy, stem cell research, and retinal implants are supporting innovation. Rising prevalence and demand for targeted treatments, coupled with regulatory incentives and orphan drug designations, are likely to boost market growth through the forecast period.
Base Year
Historical Period
Forecast Period
According to Piyush Kohli et al., 2024, Stargardt Disease (STGD) affects an estimated 10–12.5 per 100,000 individuals in the US, and 0.110–0.128 per 100,000 annually in the UK. Growing diagnosis rates are supporting market growth across the 8 major markets.
In June 2025, the FDA cleared Ocugen’s IND amendment for a Phase II/III trial of OCU410ST for Stargardt disease. Such regulatory milestone is expected to accelerate market growth by enabling faster therapy development.
The advancement of gene therapies for rare retinal diseases is a key market driver. For instance, in March 2025, SpliceBio dosed the first patient with SB-007, a dual AAV gene therapy for Stargardt disease, enhancing growth in markets.
Compound Annual Growth Rate
7.2%
Value in USD Million
2026-2035
*this image is indicative*
Stargardt disease (STGD) is a rare inherited retinal condition that affects the macula, leading to gradual central vision loss, typically beginning in childhood or adolescence. It is caused by mutations in the ABCA4 gene, resulting in the accumulation of toxic substances in the retina that damage photoreceptor cells. The market is witnessing significant growth driven by advancements in gene therapy, stem cell treatments, and increased clinical research activities. The market is poised to reach USD 521.66 Million by 2035. Rising awareness, improved genetic testing, and expanding healthcare infrastructure further support market expansion.
Robust Clinical Advancements to Fuel the Growth in the Market
The progression of innovative clinical trials is a key growth driver for the market. For instance, in June 2024, Belite Bio received approval from the UK’s MHRA to initiate its second clinical trial (DRAGON II) for Tinlarebant, an oral therapy targeting adolescent STGD1 patients. This milestone builds upon promising data from a previous Phase 2 trial that demonstrated sustained lesion reduction over 24 months. With global Phase 3 enrollment completed and interim data expected in Q4 2024, the therapy’s progress underscores rising regulatory support and growing therapeutic potential. These advances are expected to significantly boost confidence in novel therapies and drive accelerated market expansion across key regions.
Some of the trends in the market include regulatory acceleration, addressing unmet medical needs, and rapid innovations in gene therapy.
Regulatory Acceleration and Unmet Needs to Impact the Market Landscape Positively
The market across the 8 major markets is poised for growth, fueled by increasing regulatory support and the urgent need for effective treatments. In January 2025, the U.S. FDA granted Rare Pediatric Disease and Fast Track designations to gildeuretinol, a vitamin A substitute developed by Alkeus Pharmaceuticals. These designations reflect the agency’s recognition of the unmet medical need in STGD, which affects over 150,000 people globally with no approved therapies. This regulatory momentum is expected to accelerate drug development timelines, improve market access, and attract greater investment, factors that are likely to drive substantial growth in the STGD market in the coming years.
Accelerated Gene Therapy Innovations to Boost Stargardt Disease Market Value
The growing focus on pediatric gene therapy advancements is a significant trend in the market. This momentum is fueled by increasing regulatory support and novel therapeutic strategies. In May 2025, Ocugen received the U.S. FDA’s Rare Pediatric Disease Designation for its modifier gene therapy candidate, OCU410ST, targeting ABCA4-associated retinopathies, including Stargardt disease. The designation paves the way for accelerated development and potential market exclusivity. This trend is expected to drive notable growth in the Stargardt Disease market.
Assistive Technology and Software Expected to Lead the Market by Treatment Type
The market comprises several treatment types, including optical and digital vision aids, supplements, light and glare management products, assistive technology and software, and others. Each category targets specific symptoms of central vision loss and photoreceptor degeneration associated with STGD. Among these, assistive technology and software are expected to lead the market, driven by growing integration of AI-powered vision assistance tools and increasing demand for user-friendly, portable digital solutions. In October 2024, researchers at the Indian Institute of Technology Madras (IIT Madras) developed an enhanced drug delivery technique using mild laser heating to improve treatment efficacy for retinal disorders. This innovation highlights the growing convergence of engineering and vision sciences and the role of assistive technologies in improving clinical outcomes. With nearly 11 million individuals affected by retinal disorders in India alone, the rising use of simulation-based tools and software in treatment planning is reinforcing the market dominance of assistive technology in managing Stargardt disease and similar retinal conditions.
The market is divided into regions such as the United States, the United Kingdom, Germany, France, Italy, Spain, Japan, and India. Among these, the United States is expected to lead the market. This growth is driven by advanced healthcare infrastructure, strong regulatory support, and significant research and development investments. Active patient advocacy networks, rapid adoption of new therapies, and favorable reimbursement policies further strengthen the market. For instance, in May 2025, the U.S. FDA granted Breakthrough Therapy Designation to Tinlarebant. This followed promising data from the global phase 3 DRAGON trial, emphasizing the country’s leadership in accelerating novel STGD treatments. These combined strengths firmly position the United States as a key driver in shaping the future of the STGD therapeutics market.
The key features of the market report comprise clinical trials analysis, patent analysis, funding and investment analysis, and strategic initiatives by the leading players. The major companies in the market are as follows:
eSight Corporation, a leader in low vision assistive technology, offers the eSight Go™, a clinically validated digital medical device designed to enhance vision for individuals with central vision loss, including those affected by Stargardt disease (STGD). Registered with the FDA and EUDAMED, eSight Go™ uses a high-definition camera and proprietary software to optimize real-time visual input. The device has demonstrated significant improvements in distance acuity, reading, and facial recognition, positioning eSight as an impactful contributor in the STGD market.
OrCam Technologies, a leader in assistive technology, has developed OrCam MyEye 2, a breakthrough wearable device designed for individuals with visual impairments, including those affected by Stargardt disease. Utilizing artificial intelligence and machine learning, the device reads text aloud and recognizes faces, objects, and money bills, significantly enhancing user independence. In the Stargardt disease (STGD) market, OrCam’s innovative solution empowers users to regain access to reading and daily activities, marking a transformative step in vision-assistive care.
Freedom Scientific Inc. is a leading provider of assistive technology for individuals with visual impairments, including those affected by Stargardt disease. The company offers a comprehensive range of products such as TOPAZ desktop video magnifiers, RUBY and SAPPHIRE handheld video magnifiers, ONYX portable video magnifiers, and MAGic screen magnification software. These solutions support individuals with central vision loss by enhancing visual accessibility in daily tasks. Freedom Scientific’s technologies are widely used by patients with juvenile macular degeneration to maintain independence across educational, occupational, and personal settings.
Enhanced Vision is a leading developer of assistive technology for individuals with low vision, including those affected by Stargardt disease (STGD). The company offers advanced visual aids such as the Acrobat LCD and the Pebble handheld video magnifier, which significantly enhance daily functionality for people experiencing progressive vision loss. Through its innovative products, Enhanced Vision supports the Stargardt disease market by improving visual accessibility and quality of life for legally blind individuals.
*Please note that this is only a partial list; the complete list of key players is available in the full report. Additionally, the list of key players can be customized to better suit your needs.*
Other key players in the market include NoIR Insight, Envision, Orbit Research, Bausch + Lomb, Naturebasics, and WellthyLife.
The market report offers a detailed analysis of the market based on the following segments:
Market Breakup by Treatment Type
Market Breakup by Age Group
Market Breakup by Distribution Channel
Market Breakup by Country
Upto 15% Off
USD
$5499 $4949
$3299 $2969
$6999 $5949
$8199 $6969
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
| REPORT FEATURES | DETAILS |
| Base Year | 2025 |
| Historical Period | 2019-2025 |
| Forecast Period | 2026-2035 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Treatment Type |
|
| Breakup by Age Group |
|
| Breakup by Distribution Channel |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Supplier Landscape |
|
| Companies Covered |
|
Single User License
One User
USD 5,499
USD 4,949
tax inclusive*
Datasheet
One User
USD 3,299
USD 2,969
tax inclusive*
Five User License
Five User
USD 6,999
USD 5,949
tax inclusive*
Corporate License
Unlimited Users
USD 8,199
USD 6,969
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Share